The primary tumor in the lung must be biopsy confirmed non-small cell lung cancer within  days of randomization
Part B: Patient with Non-Small Cell Lung Cancer (NSCLC), Endometrial cancers, and MSI-H solid tumors.
Advanced Non Small Cell Lung Cancer (NSCLC)
No prior radiotherapy or chemotherapy (except for the chemotherapy described in the bullet above) for small cell lung cancer (SCLC)
Pathologically confirmed non-squamous non-small cell lung carcinoma (NSCLC)
Participants must have a pathologically-confirmed diagnosis of non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC).
Non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)
Non-small cell lung cancer (NSCLC) (adenocarcinoma)
Participants with unilateral pleural effusion (other than non-small cell lung cancer [NSCLC] indication) should fulfill the following criteria for pulmonary and cardiac functions: Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification  ?  level and New York Heart Association (NYHA) classification class 
Non-small cell lung adenocarcinoma or squamous cell carcimona
Non-small cell lung carcinoma;
Small cell lung cancer
Participants with small cell lung cancer, lymphoma, or myeloma
Patients with prior history of either small cell lung cancer or NSCLC regardless of the treatment received, other than patients who have recurrent disease following resection
Small Cell Lung Carcinoma
Diagnostic of small cell lung cancer
Histologic diagnosis of a non-small cell lung cancer or lung metastasis from a solid tumor; one biopsy site is adequate for multiple sites of thoracic disease
Small cell lung cancer (SCLC).
Component of small-cell cancer or sarcomatoid cancer
Confirmed locally advanced and/or metastatic solid tumor, with at least one tumor lesion of non-critical location accessible to biopsy (with exception of non-small cell lung cancer [NSCLC] participants), and with confirmed progression at baseline that has progressed on, or participant is intolerant to, the standard of care therapy
Pathologically confirmed invasive non-small cell lung cancer within  weeks prior to study registration. OR Pathologically confirmed invasive non-small cell lung cancer within  months prior to study registration if the patient received induction chemotherapy.
COHORT B GROUP : NON-SMALL CELL LUNG CANCER: Patients must have advanced non-small cell lung cancer with mutant KRAS
COHORT B GROUP : NON-SMALL CELL LUNG CANCER: Patients must have failed a minimum of one previous line of chemotherapy for advanced disease
COHORT B, GROUP : NON-SMALL CELL LUNG CANCER: Patients must not have clinical significant hemoptysis
Limited primary non-small cell lung cancers (NSCLCs) (TaNM, TbNM, TaNM, TbNM, or TNM) or metastatic lung tumors with no evidence of uncontrolled extrathoracic metastases
Biopsy-proven non-hematopoietic malignancy, except for germ cell cancer. Small cell lung carcinoma is eligible for this study.
Greater than  lines of prior systemic therapy for metastatic non-small cell lung cancer
Prior treatment with osimertinib or other drugs that target EGFR mutant non-small cell lung cancer (including erlotinib, afatinib, gefitinib, rocelitinib)
Stage IIIB/IV or recurrent non-small cell lung cancer which is not amenable to curative intent therapy
Histologically or cytologically confirmed non-small cell lung cancer; if a diagnostic biopsy is available, a pre-treatment biopsy is not required. Patients with a suspected lung cancer may be consented, but pathology must be confirmed prior to initiating treatment on study. Neuroendocrine carcinomas (e.g. small cell lung cancer [SCLC], carcinoid tumors) are not eligible. Carcinomas with neuroendocrine differentiation are eligible.
Participants must have a pathologically-confirmed diagnosis of non-small cell lung cancer (NSCLC)
Has metastatic non-small cell lung cancer
Newly diagnosed, untreated, biopsy proven non-small cell lung cancer
Patients with metastatic or node positive non-small cell lung cancer (NSCLC)
Histological confirmation of non-small cell lung cancer
Unresectable stage - non-small cell lung cancer (based on computed tomography/positron emission tomography [CT/PET], magnetic resonance imaging [MRI] or CT of brain, and physical exam);\r\n* Eligible if recurrence after surgery and now has the equivalent stage - non-small cell lung cancer (NSCLC) OR had sub totally resected stage - NSCLC
Histologic/cytologic documentation of non-small cell lung cancer (NSCLC)
Histological or cytological evidence of stage IV non-small cell lung cancer (NSCLC) (any histology)
Has a pathologically proven recurrent or metastatic non-squamous non-small cell lung cancer
Patients may not be receiving any other investigational agents for the treatment of non-small cell lung cancer
Patients with pathologically proven non-small cell lung cancer
Primary small cell lung cancer, myeloma, lymphoma, leukemia, or other histologies not optimally treated with SRS
Pathologically proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within  years of registration; patients with metastasis of unknown primary tumor are permitted
Platinum sensitive relapsed small cell lung cancer (module )
INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients with non-small cell lung cancer that is metastatic or inoperable and who have been treated with at least one line of prior therapy or declined conventional therapy
Recurrent or progressive advanced stage non-small cell lung cancer (no small cell component); NOTE: pathology reports documenting the diagnosis of NSCLC are required to be reviewed to confirm outside diagnosis
Biopsy-proven non-hematopoietic malignancy, except for small cell lung cancer, germ cell cancer, or unknown primary tumor
Newly diagnosed, histologically proven (or strongly suspected, see below) T-TaNM (Stage IA-IB) non-small cell lung cancer (NSCLC), with maximum tumor diameter =<  cm under consideration for stereotactic ablative body radiotherapy (SABR) as definitive primary treatment
Prior use of platinum or paclitaxel for stage IV non-small cell lung cancer (NSCLC) or concurrent use of other anticancer approved or investigational agents
Patients with any component of small cell lung carcinoma
Histological/cytological diagnosis of non-small cell lung cancer (NSCLC). Squamous cell (epidermoid), adenocarcinoma, bronchoalveolar carcinoma and large cell anaplastic lung carcinoma histologies are eligible. Mixed histologies of NSCLC (i.e., adenosquamous) are eligible. Mixed NSCLC/small cell lung carcinoma (SCLC), and variant large and small cell lung cancer are NOT eligible for this study.
Advanced stage non-small cell lung cancer (NSCLC)
Histologic or cytologic diagnosis of adenocarcinoma non-small cell lung cancer
Stage IV non-small cell lung cancer or recurrent disease which cannot be approached with curative intent
Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung. according to WHO Classification of Tumours (WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. WHO/IARC Classification of Tumours, th Edition, Volume ). Patients with large-cell neuroendocrine carcinomas are not eligible.
A combination of small cell and non-small cell lung cancer, pulmonary carcinoid tumour or large-cell neuroendocrine carcinoma (LCNEC).
Phase II: extensive stage small cell lung cancer with progression or recurrence after exactly one platinum-containing regimen. Patients who progressed during or within one month of completing platinum-based chemotherapy will be excluded. Patients who received primary curative chemoradiation therapy for limited disease, but who recur within the primary tumor site, previously radiated field or with distant metastases are also allowed to participate. Patients who have clinical evidence of recurrent small cell lung cancer do not require a confirmatory biopsy to be eligible for this trial. Prior irinotecan is not allowed.
Have a prior histologic diagnosis of cancer other than small cell lung cancer, lymphoma, and germ cell histologies
Any primary is eligible with exception of small cell lung cancer, lymphoma, and germ cell histologies
Small cell lung cancer, lymphoma, and germ cell histologies
Histologic or cytologic confirmation of lung cancer (squamous, ras-mutated adenocarcinoma or small cell lung cancer)
Pathologically proven diagnosis of unresected stage II-IIIB, or recurrent after surgical resection or stereotactic body radiation therapy (SBRT) non-small cell lung cancer
Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue
Diagnosis of non-small cell lung cancer.
Patients with small cell lung cancer and lymphoma are ineligible
Pathologically proven diagnosis of small cell lung cancer (SCLC)
Part : advanced stage solid tumors; Part : non-small cell lung cancer (NSCLC), pancreatic cancer and cutaneous melanoma
Confirmed locally advanced or metastatic non-small cell lung cancer that is unresectable
For the expansion cohort of non-small cell lung cancer (NSCLC) patients previously treated with and having progressed on immunotherapy patients must have no standard of care option available or have contraindications to such treatment (including those who decline such treatment)
Recurrent non-small cell lung cancer
Histological or cytological confirmed squamous or non-squamous non-small cell lung cancer.
Patients with measurable inoperable, histologically confirmed non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), esophageal carcinoma, thymic epithelial neoplasms, germ cell tumors, malignant pleural mesotheliomas or chest wall sarcomas, as well as patients with gastric, colorectal, pancreas or renal cancers, germ cell tumors and sarcomas metastatic to thorax are eligible
Radiosensitive or non-solid (eg. small cell lung carcinomas, germ cell tumors, leukemias, or lymphomas) or unknown tumor histologies
Histologic confirmation of non small cell lung cancer or other solid primary tumor metastatic to lungs
Medically inoperable stage I or II non small cell lung cancer with negative lymph nodes or metastatic cancer to lung with less than or equal to  lesions
Pathologically (histologically or cytologically) proven diagnosis of stage IIIA or IIIB non-small cell lung cancer within  days of registration; eligible histologies include adenocarcinoma, adenosquamous, large cell carcinoma, squamous carcinoma, non-lobar and non-diffuse bronchoalveolar cell carcinoma or non-small cell lung cancer not otherwise specified [NOS])
Radiosensitive primary tumor such as small cell lung cancer, germ cell tumors, lymphoma, leukemia, or multiple myeloma
Patients with any component of small cell lung carcinoma are excluded
Radiosensitive (eg. small cell lung carcinomas, germ cell tumors, leukemias, or lymphomas) or unknown tumor histologies
Diagnosis of non-small cell lung cancer
Diagnosed with stage IV Non-Small Cell Lung Cancer
Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options.
Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC):
Patients with a histologically confirmed diagnosis of non-small cell lung cancer (NSCLC), including neuroendocrine tumors or small cell lung cancer (SCLC) who are being evaluated for palliative WBRT (with or without neurosurgical resection or stereotactic radiosurgery [SRS]) for radiologically or histologically diagnosed brain metastases presumed to be from the lung cancer are eligible for this Phase I study; group  will only include NSCLC patients
Advanced non-small cell lung cancer
Histologically or cytologically documented non-small cell lung cancer (NSCLC), including squamous cell carcinoma, adenocarcinoma (including bronchioloalveolar carcinoma), and large cell anaplastic carcinoma (including giant and clear cell carcinomas) and poorly differentiated (not otherwise specified, NOS) non-small cell lung cancer; totally resected tumors are excluded\r\n* Patients must be M;\r\n* Patients with T or T disease with N or TN- disease (stage IIIA) are eligible\r\n* Patients with T with any N or any T with N disease are eligible (stage IIIB)\r\n* Measurable disease is required
non-small-cell adenocarcinoma of the lung
Diagnosis of melanoma or other non-epithelial based malignancy such as sarcoma, neuroendocrine tumor, small cell lung cancer
Small cell cancer not lung in origin
Any ongoing toxicity ? Grade  attributable to prior Non-Small-Cell Lung Cancer (NSCLC) treatment
For all Parts: The participant must have stage IV non-small cell lung cancer (NSCLC).
Histologic confirmation of metastatic non-small cell lung cancer (NSCLC) and confirmed ALK rearrangement.
Non-small cell lung adenocarcinoma
Pathologic evidence of chemo-resistant Small Cell Lung cancer (relapse < days after st line), chemo-sensitive Small Cell Lung Cancer (relapse > days after first line), locally advanced metastatic neuroendocrine tumor of gastro-entero, pancreatic, pulmonary (other than Small Cell Lung) or thymic origin, or advanced renal cell carcinoma for which everolimus is indicated.
Non-small cell lung cancer
Must have received or been previously offered standard first-line chemotherapy for advanced non-small cell lung cancer
Group : Patients with BRAF mutated cancer, except those with colorectal or non-small cell lung cancers
Group : Patients with BRAF mutated non-small cell lung cancer
Histological diagnosis of non-small cell lung cancer (NSCLC). Squamous cell (epidermoid), adenocarcinoma, bronchoalveolar carcinoma, and large cell anaplastic lung carcinoma histologies are eligible as are mixed histologies of NSCLC (i.e., adenosquamous). Mixed NSCLC/small cell lung carcinoma (SCLC), and variant large and small cell lung cancer are not eligible.
Prior chemotherapy or treatment for metastatic non-small cell lung cancer
Patients with measurable brain metastasis not resulting from small cell lung cancer and germ cell malignancy
Part B: Non-small cell lung cancer of any subtype that is advanced and/or metastatic
Pathologic diagnosis of non-small cell lung cancer prior to enrollment
Advanced biopsy-proven metastatic non-small cell lung cancer
The primary tumor is small-cell lung cancer, lymphoma, leukemia, or multiple myeloma
Diagnosis of small cell carcinoma of the lung, squamous cell carcinoma of the lung or NSCLC NOS
Prior systemic anti-cancer therapy for small cell lung cancer
The participant has a solid tumor. Parts  and  are limited to participants with non-small cell lung cancer. Part  is limited to participants with small cell lung, head and neck, pancreatic, colorectal, and cervical cancers
Patients with CNS refractory small cell lung cancer having received standard recommended dosing for either of the two therapies:\r\n* Whole brain radiation therapy (WBRT)\r\n* Prophylactic cranial irradiation (PCI)
Individuals with KRAS-mutated metastatic or recurrent non-small cell lung cancer
NSCLC (Non-small-cell lung cancer): Patients with NSCLC and known KRAS status after platinum based chemotherapy.
Molecular characterization of non-squamous non-small cell lung cancer will be recommended prior to enrollment per standard of care/institutional guidelines; consistent with current National Comprehensive Cancer Network (NCCN) guidelines and the recent Food and Drug Administration (FDA)-approval indication of erlotinib for first-line treatment of advanced non-small cell lung cancer in persons with tumor EGFR mutations, participants who have known EGFR sensitizing mutations in tumors will be permitted to enter the study and receive erlotinib as initial monotherapy; for participants who have received one or more prior lines of chemotherapy, molecular characterization of tumors is required whenever possible with an understanding that inability to obtain sufficient tissue specimen for characterization will not preclude enrollment into the study
Histologic or cytologic confirmed locally advanced or metastatic small cell lung cancer, ovarian cancer, or cervical cancer (Part ); small cell lung cancer and ovarian cancer (Part )
Patients with ovarian and small cell lung cancer must have failed initial therapy
Pathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within  years of registration; if the original histologic proof of\r\nmalignancy is greater than  years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease)
Patients with measurable brain metastasis(es) resulting from small cell lung cancer and/or germ cell malignancy
Non-small cell lung cancer metastatic to the pleura that extends outside of the pleura requiring immediate therapy
Part B: Non-small cell lung cancer (squamous or non-squamous)
For Part B (non-small cell lung cancer) only:
Non-small cell lung cancer
Small cell lung cancer
Patients must have histological or cytological confirmed primary non-small cell lung cancer (adenocarcinoma, large cell carcinoma, squamous, or unspecified); disease must be stage IV non-small cell lung cancer (NSCLC); disease may be either newly diagnosed or recurrent after previous surgery and/or irradiation; primary or metastatic site for biopsy is allowed
 weeks from surgery for stage  or  Non Small Cell Lung Cancer
Patients must understand the nature of the study and be willing to sign an informed consent that complies with the investigator/DEKK-TEC policies and approved by the Human Investigation Review Committee. Patients must have CNS involvement - from a malignancy. Lung cancer may be either small cell or non-small cell.
Diagnosis of stage IV non-small cell lung cancer, or stages II-III NSCLC that cannot be treated curatively with standard techniques
Non-small cell lung cancer (NSCLC) that is either EGFR or ALK mutated
Histologic or cytologic confirmation of non-small cell lung cancer (NSCLC)
Pathologic evidence of Small Cell Lung Cancer, or Non-Small Cell Lung Cancer.
Subjects in the Phase  portion must have squamous cell Non-Small Cell Lung Cancer (NSCLC)
Must have Non-small Cell Lung Cancer with ALK+ mutation or other mutations or rearrangements potentially sensitive to crizotinib
Histologically confirmed non-small cell lung cancer with < % squamous-cell non-small cell lung cancer or colorectal cancer for which no potentially curative treatment options are available
The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable
A minimum of  Squamous Non-Small Cell Lung Cancer (Sq-NSCLC)
Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
Radiosensitive or non-solid (eg. small cell lung carcinomas, germ cell tumors, leukemias, or lymphomas) or unknown tumor histologies
The participant's tumor fully or partially contains Small Cell Lung Cancer (SCLC).
Tumor wholly or partially contains small cell lung cancer
Histologically confirmed non-small cell lung cancer (NSCLC) or metastasis from another known or unknown primary by biopsy, or recurrent tumors in the setting of prior RFA/microwave or cryotherapy; eligible histological subtypes include: squamous cell carcinoma, adenocarcinoma, large cell neuroendocrine, and non-small cell carcinoma not otherwise specified
Patients that have a probable diagnosis of non-small cell lung cancer, of any stage, with obstructive or hemorrhagic endobronchial disease will be considered for enrollment
Centrally located non-small cell lung cancers and squamous cell lung cancers
Biopsy proven non-small cell lung cancer
For dose expansion cohort, patients must have histologic or cytologic confirmed non-small cell lung cancer that are not curable
PATIENT: Diagnosed with advanced non-small cell lung carcinoma (NSCLC) being treated with non-curative intent, and informed of advanced disease within the prior eight weeks
Diagnosis of stages II-IV non-small cell lung cancer (NSCLC)
A diagnosis of either non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or mesothelioma, not being treated with a curative intent
Patient has stage B or  non-small cell lung cancer (NSLC) or extensive stage small cell lung cancer (SCLC) and is within one month of treatment initiation
Pathologically proven solid tumor malignancy (except for small cell lung cancer [SCLC], germ cell tumor)
Diagnosed with advanced non-small cell lung cancer (NSCLC), small cell lung cancer, or mesothelioma, being treated with non-curative intent, and informed of advanced disease within the prior eight weeks
PATIENTS ONLY: Diagnosed with stage IV non-small cell lung cancer (NSCLC)
Diagnosed with advanced non-small cell lung cancer (NSCLC), small cell lung cancer, or mesothelioma, being treated with non-curative intent, and informed of advanced disease within the prior eight weeks
PATIENT: Confirmed incurable lung cancer (non-small cell lung cancer [NSCLC], small cell lung cancer, or mesothelioma) or non-colorectal gastrointestinal (GI) cancer (esophageal, gastric, hepatic, biliary, or pancreatic or GI unknown primary) not being treated with curative intent
Patient is at least  weeks post-diagnosis of stage III or IV non-small cell or extensive small cell lung cancer and has received care at the Indiana University Simon Cancer Center or another Indiana University Health hospital or clinic
Confirmed metastatic lung cancer (non-small cell lung cancer [NSCLC], small cell lung cancer [SCLC], and mesothelioma [meso]) or non-colorectal gastrointestinal (GI) cancer (esophageal, gastric and hepatobiliary) not being treated with curative intent
Patients with measurable brain metastasis(es) resulting from small cell lung cancer and/or germ cell malignancy
Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer
Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer
Participants should preferably have histologically confirmed non-small cell lung cancer, but patients with a clinical and radiographic diagnosis of non-small cell lung cancer who are candidates for stereotactic body radiation therapy may also be eligible
Patients with early non-small cell lung carcinoma, or clinically-diagnosed early stage lung cancer, or pulmonary metastases
Subject has histologic or cytologic confirmation of lung cancer (non-small cell lung cancer [NSCLC] or small cell) and has been recommended thoracic radiotherapy as part of standard of care management
Patients receiving once daily fractionated intrathoracic radiation therapy for:\r\n* Stage IIA-IIIB non-small cell lung cancer\r\n* Limited stage small cell lung cancer\r\n* Stage I-III esophageal cancer (neoadjuvant or definitive)\r\n** For esophageal patients, accrual will be limited to patients that are NOT receiving trastuzumab
Patients with small cell lung cancer receiving twice daily (b.i.d.) radiation
Patients undergoing SABR for the treatment of a lung tumor, inclusive of non-small cell lung cancer or lung metastases
Confirmed diagnosis of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)
Biopsy proven non-small cell lung cancer
Primary or locally recurrent stage I-IIA non-small cell lung cancer (NSCLC): T-T N M; tumor must be large enough to be above the detection threshold of PET imaging as determined by study investigators
Advanced small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of lung progressed after at least  line of anticancer chemotherapy
A primary histopathological and/or cytopathological diagnosis of small cell lung cancer (SCLC)
Patient must have proven or suspected non-small cell lung cancer (NSCLC) (squamous cell, adenocarcinoma, or large cell) and be clinical stage I or II, according to the  staging system of the American Joint Commission on Cancer for lung cancer (T- N, T- N)
All patients with early stage (stage I-III) non-small cell lung cancer, adenocarcinoma histology
Diagnostic of small cell lung cancer or carcinoid tumors
Non-small cell lung cancer (NSCLC).
Part : Subjects with advanced or metastatic adenocarcinoma of endometrium, melanoma, non-small cell lung cancer, and renal cell carcinoma
